TargetBeta
ANGPT2
angiopoietin 2 · also Ang2 · Receptor ligands
2 programs in company-led studies act on ANGPT2, from 2 companies: 0 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| faricimabrule | Hoffmann-La Roche | phase 4 | 172 running | VEGFA | NCIt |
| GENSCI148rule | Changchun GeneScience Pharmaceutical | phase 1 | 11 running | – | the studies' text |
Also acted on by the same programs
Conditions their studies are in
- Choroidal Neovascularization, 1 program
- Macular Degeneration, 1 program
- Macular Edema, 1 program
- Retinal Vein Occlusion, 1 program
- Wet Macular Degeneration, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jan 26, 2027faricimab · Hoffmann-La Roche · phase 4 · NCT05224102
- Jun 2028GENSCI148 · Changchun GeneScience Pharmaceutical · phase 1 · NCT07817615
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.